Re-LuPSMA: Interim Safety Analysis of the Prospective Phase II Trial of 177Lu-PSMA-617 Retreatment in #mCRPC. Presented by Johanna Enke, MD, #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4i3xD2l #ProstateCancer @myESMO